CytomX Therapeutics, Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 42/100
What the filing says
CytomX amended its November 2022 Collaboration and License Agreement with Regeneron via Amendments 3 and 4 (effective May 16 and May 31, 2026). Amendment 3 extended the period for Regeneron to nominate certain Collaboration Programs. Amendment 4 extended that selection period further and added additional Collaboration Programs to the agreement, with Regeneron gaining the option to nominate additional programs and paying CytomX undisclosed fees upon exercise. Most financial and operational specifics are redacted as competitively sensitive.
Why this rating
Regeneron is a $373B pharma giant; CytomX is $372M. Extension and expansion of an existing collaboration is meaningful for CytomX but lacks disclosed financial terms or material business change indicators. Neutral pending future milestone/revenue realization.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.